Abstract : Objective To explore the clinical effect of Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) combined with recombinant human epidermal growth factor in the treatment of refractory skin ulcers in patients with diabetes. Methods 78 patients with refractory diabetic skin ulcers treated in this hospital from February 2018 to February 2020 were listed as research subjects. The patients were randomly divided into a conventional group and an observation group according to the random number table method, with 39 cases in each group. All are two degrees deep. Patients in the conventional group were treated with Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin), while the observation group was treated with Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) combined with recombinant human epidermal growth factor. The treatment conditions (clinical indicators, ulcer healing status, and treatment effectiveness) of the two groups of patients were analyzed and compared. Results The treatment effectiveness rate of the observation group was 97.44%, which was significantly higher than that of the conventional group, and the difference was statistically significant (χ ~2=7.341, P=0.007); the ulcer area, quality of life score, fasting blood glucose, and 2 h after meal in the observation group The blood glucose level, ulcer healing rate, average desiccation time, average myogenic time, average healing time, and number of dressing changes were (3.54±1.76) cm2, (82.98±10.62) minutes, (4.25±0.73) mmol/L, and ( 5.36±1.62) mmol/L, (60.13±2.14)%, (13.84±4.80) d, (15.15±7.03) d, (26.66±7.28) d, (18.82±3.80) times, significantly better than the conventional group, The difference is statistically significant (t=8.830, 8.138, 10.706, 8.246, 82.288, 8.462, 10.623, 8.307, 8.693, P<0.001). Conclusion: Treatment of patients with refractory skin ulcers in diabetes using Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) combined with recombinant human epidermal growth factor can improve the patient's blood sugar level and improve the patient's quality of life. The patient's ulcer heals well and has high clinical application value.
Yan Xiaohang. Effect analysis of compound polymyxin B ointment combined with recombinant human epidermal growth factor in the treatment of diabetic skin refractory ulcers[J]. New World of Diabetes, 2022, 25(01): 1-4.